阅读说明：本技术 用于高度近视视网膜病变预防及治疗的光生物调节治疗仪及使用方法 (Photo-biological regulation therapeutic apparatus for preventing and treating high myopia retinopathy and use method thereof ) 是由 朱勤 牛志强 寸青 陈琴 钟华 陶奕瑾 于 2021-01-12 设计创作，主要内容包括：本发明公开一种用于高度近视视网膜病变预防及治疗的光生物调节治疗仪及使用方法,通过设定左右眼视镜相对发光视点亮度为600-800nm波长的近红外光,增加进入小叶的血流量,从而使微循环血量增加,改善眼底缺氧,为巩膜提供充足的氧,减少脉络膜下新生血管形成,为患者的视力恢复提供更大的可能性。使用方法为患者双眼在发光视点下,用近红外光对高度近视患者视网膜进行照射,每天4次,每次40秒。本发明的技术方案安全性较高,患者治疗成本较低,有利于普及。(The invention discloses an optical biological regulation therapeutic apparatus for preventing and treating high myopia retinopathy and a using method thereof, wherein the blood flow entering the lobule is increased by setting the brightness of the relative luminous viewpoints of a left eye sight glass and a right eye sight glass as near infrared light with the wavelength of 600-800nm, so that the microcirculation blood volume is increased, the fundus hypoxia is improved, sufficient oxygen is provided for the sclera, the formation of new blood vessels under the choroid is reduced, and the possibility for recovering the vision of a patient is increased. The application method comprises irradiating retina of highly myopic patient with near infrared light for 40 s 4 times per day at both eyes of the patient from the light-emitting viewpoint. The technical scheme of the invention has higher safety and lower treatment cost for patients, and is beneficial to popularization.)

1. The optical biological regulation therapeutic apparatus for preventing and treating high myopia retinopathy is characterized in that the blood flow entering the lobule is increased by setting the brightness of the relative luminous viewpoints of the left and right eye scopes as near infrared light with the wavelength of 600-.

2. The photo-biological regulation therapeutic apparatus for the prevention and treatment of high myopia retinopathy according to claim 1, wherein the light emitting viewpoint is near infrared light of 630nm ± 10 nm.

3. The method of using the photobioregulatory therapeutic device for the prevention and treatment of high myopia retinopathy of claim 1 wherein the patient's retina is irradiated with near infrared light 4 times a day for 40 seconds in both eyes at the point of illumination.

Technical Field

The invention relates to a device for preventing and treating high myopia retinopathy, in particular to a photo-biological regulation therapeutic apparatus for preventing and treating the high myopia retinopathy and a using method thereof.

Background

It has been reported that up to 61.7% of high myopia is found with fundus changes, when the fundus presents with choroidal atrophy or more severe manifestations, known as pathological myopia, whose major complications include high myopia macular degeneration, myopia traction macular degeneration and myopia optic neuropathy, which can cause irreversible damage or even loss of vision. The pathological change of the macular area directly caused by the high myopia is called high myopia macular degeneration, and is one of the main reasons of low vision and even blindness of the old. The high myopia macular degeneration is an irreversible organic change, has no effective recovery treatment means for the disease per se at the present stage, and can only perform corresponding treatment on the complications of the disease, so as to prevent the disease from further progressing and further destroy the visual function. Among the manifestations of highly myopic maculopathy, CNV, severe choroidal atrophy and even macular atrophy have irreversible severe damage to visual function and are therefore considered to be manifestations of severe impairment of visual function, requiring early intervention. CNV is related to local ischemia and hypoxia, and earlier treatment schemes including laser photocoagulation, photodynamic therapy, surgical resection, macular displacement and the like are treatment schemes for improving local ischemia and hypoxia environment. These treatments are generally poor in outcome, do not provide significant visual improvement, and instead have a high risk of myopia recurrence. After the anti-vascular endothelial growth factor (anti-VEGF) drugs are available, anti-neovascular drug therapy has become the first choice for the treatment of high myopia CNV. The anti-angiogenesis medicine has definite curative effect on improving vision, and patients keep good visual function in the long-term follow-up process, but because the medicine needs to be injected into eyes, the risk of operation of the eyes exists, the treatment price is high, and many patients cannot bear the disease.

Near Infrared (NIR) light therapy, a method of use based on photobioregulatory devices (PBMT), has recently gained widespread attention in ophthalmology as a new scientific treatment. This therapeutic technique using near-infrared therapy has benefited greatly from significant advances in the fields of photobiology and bioenergetics, such as the discovery of cytochrome c oxidase photoneuromodulation and the elucidation of therapeutic biochemical processes.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide a photo-biological regulation therapeutic apparatus for preventing and treating high myopia retinopathy and a using method thereof.

The invention is realized by the following steps:

the photo-biological regulation therapeutic equipment for preventing and curing high myopia retinopathy is characterized by that it utilizes the near-infrared light whose relative luminous viewpoint brightness of left and right visual glasses is 600-800nm wavelength to increase blood flow quantity entering lobule so as to increase microcirculation blood quantity, improve fundus hypoxia, provide sufficient oxygen for sclera, reduce formation of choroidal neovascularization and provide greater possibility for recovering vision of patient.

Further, the luminous viewpoint is near infrared light of 630nm ± 10 nm.

The use method of the optical biological regulation therapeutic apparatus for preventing and treating the high myopia retinopathy comprises the following steps:

the retina of a patient with high myopia is irradiated by near infrared light 4 times a day for 40 seconds each time under the light-emitting viewpoints of both eyes of the patient.

The invention has the following advantages and positive effects:

the near infrared light is near infrared light in the spectral range of 600-1100nm generated by a Light Emitting Diode (LED). The intracellular photoreceptor is sensitive to the wave band (especially 600-700nm is an optical window for in-vivo treatment, the penetrating power is strong but not enough to cause tissue cell damage), and the light energy is converted into the metabolic energy by activating the intracellular photoreceptor, triggering a signal channel and influencing the cell metabolism. Near infrared light has been shown to significantly increase the activity of cytochrome oxidase and superoxide dismutase, suggesting beneficial effects in inducing metabolism and antioxidant effects. In addition, near infrared light may also promote cerebral blood flow and cognitive function in humans without adverse effects.

The occurrence and development of highly myopic maculopathy are mainly related to the elongation of the axis of the eye, the retroscleral staphyloma, the choroid thickness, the age and the like. Among them, hyperelongation of the axis of the highly myopic eye and retroscleral staphyloma are major risk factors for the development of highly myopic maculopathy. On the one hand, the axis of the eye continues to elongate with age, with progressive stretching resulting in thinning of the choroid, and on the other hand, the choroid becomes physiologically thinner with age. And choroidal thinning further contributes to the development of highly myopic maculopathy. The near infrared light has a warming effect, can narrow and open a bottleneck at the arteriolar opening of the choroid lobule, and increases blood flow volume entering the lobule, so that microcirculation blood volume is increased, fundus hypoxia is improved, sufficient oxygen is provided for sclera, and formation of choroidal neovascularization is reduced. In addition, the increase of choroidal blood flow and the thickening of choroid are also protective factors of high myopia retinopathy, and can reduce the formation of new blood vessels under choroid and reduce high myopia macular degeneration. The treatment scheme has higher safety, and the low-dose red light is used for treating the myopia for decades. In addition, the low-dose red light therapeutic apparatus has lower price and low treatment cost for patients, and is beneficial to popularization.

Drawings

FIG. 1 is a schematic view of the biological regulating apparatus of the present invention.

In the figure: 1-luminous viewpoint, 2-left and right sight glasses.

Detailed Description

The present invention is further illustrated by the following examples in connection with specific embodiments thereof, it is to be understood that these examples are intended only for the purpose of illustration and are not intended to limit the scope of the invention, which is to be given the full breadth of the appended claims as modified by those skilled in the art upon reading the present disclosure.

The specific techniques, connections, conditions, or the like, not specified in the examples of the present invention, are performed according to the techniques, connections, conditions, or the like described in the literature of the art or according to the product specification. The materials or equipment used are not indicated by manufacturers, and all are conventional products available by purchase.

A photo-biological regulation therapeutic apparatus for preventing and treating high myopia retinopathy increases blood flow entering lobules by setting the relative luminous viewpoint brightness of a left eye sight and a right eye sight to be 600-800nm near infrared light, thereby increasing microcirculation blood volume, improving fundus hypoxia, providing sufficient oxygen for sclera, and reducing the formation of choroidal neovascularization. The near infrared light has a warming effect, can narrow and open a bottleneck at the arteriolar opening of the choroid lobule, and increases blood flow volume entering the lobule, so that microcirculation blood volume is increased, fundus hypoxia is improved, sufficient oxygen is provided for sclera, and formation of choroidal neovascularization is reduced. In addition, increased choroidal blood flow, thickening of the choroid, is itself a protective factor for high myopia retinopathy. Therefore, the optical biological regulation therapeutic apparatus for preventing and treating the high myopia retinopathy of the invention is characterized in that as shown in figure 1, the brightness of the left and right eyemirrors 2 of the optical biological regulation therapeutic apparatus relative to the luminous viewpoint 1 is set as near infrared light of 600-.

The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.